OUR PROPOSAL: SYLVEE

**MOTIVATION**

Three months following hospitalization, up to 43% of COVID-19 patients report dyspnea. Respiratory symptoms left untreated can cause irreversible lung damage and progressive decline in lung function. Maintaining accurate post-acute COVID patient monitoring employing acoustic lung resonance for air trapping measurement can help understand COVID-19 sequelae and new therapy development, efficacy, safety, and side effects.

**PROJECT TEAM**

Maria Artunduaga, MD, MPH, MTM  
Principal Investigator
Luis Javier Peña, MD, Pulmonologist/Intensivist  
Subinvestigator
Karen Martínez, MD  
Clinical Operations Lead
Li Zhang, MS, PhD  
Biostatistician
Cezar Morun, PhD  
Hardware Engineering Lead
Douglas Baptista de Souza, PhD  
DSP/ML Lead

**Today's tools are inadequate!**

Our device uses next-generation technology to quantify air trapping, a well-known biomarker of lung function decline. It monitors and analyzes acoustic resonance properties in real time or stores them for later processing.

**Preliminary results:**

- Accuracy of >90% to detect respiratory rate when moving.
- Sylvee can consistently identify changes in lung resonance in COPD patients during exercise.
- The acoustic resonances and frequency shifts of patients with and without COPD differed.

**DELIVERABLES**

1) **Clinical:** Perform a semi-remote feasibility trial (n=25 COVID-19 survivors; n=25 healthy controls) to track changes in acoustic resonance properties using PFTs, metronome breathing, and the 6MWT. Also compare Sylvee’s efficacy to chest CT scan imaging, standardized questionnaires, and other clinical parameters.

2) **Academic:** Publish in a respected peer-reviewed journal like American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal or The Lancet Respiratory Medicine

3) **Regulatory:** Submit a pre-EUA package to the FDA for review before submitting an EUA.

4) **Business:** Conduct over 50 interviews with patients, healthcare providers and administrative staff to learn how to understand how our device fits into workflows and what economic data they need to see value (e.g., safety, savings, new revenue).

5) **Fundraising:** Secure 5 letters to support raising $4M from institutional investors.